Depression-like Symptoms of Withdrawal in a Genetic Mouse Model of Binge Methamphetamine Intake

Overview

Journal Genes Brain Behav

Specialties Genetics
Neurology
Social Sciences

Date 2018 Oct 31

PMID 30375183

Citations 10

Authors

Shkelzen Shabani

Bryan Schmidt

Bikalpa Ghimire

Sydney K Houlton

Laura Hellmuth

Erika Mojica

Tamara J Phillips

Affiliations

Soon will be listed here.

Abstract

Binge methamphetamine (MA) users have higher MA consumption, relapse rates and depression-like symptoms during early periods of withdrawal, compared with non-binge users. The impact of varying durations of MA abstinence on depression-like symptoms and on subsequent MA intake was examined in mice genetically prone to binge-level MA consumption. Binge-level MA intake was induced using a multiple-bottle choice procedure in which mice were offered one water drinking tube and three tubes containing increasing concentrations of MA in water, or four water tubes (control group). In two studies, depression-like symptoms were measured using a tail-suspension test and a subsequent forced-swim test, after forced abstinence of 6 and 30 hours from a 28-day course of chronic MA intake. An additional study measured the same depression-like symptoms, as well as MA intake, after prolonged abstinence of 1 and 2 weeks. MA high drinking mice and one of their progenitor strains DBA/2J escalated their MA intake with increasing MA concentration; however, MA high drinking mice consumed almost twice as much MA as DBA/2J mice. Depression-like symptoms were significantly higher early after MA access was withdrawn, compared to levels in drug-naïve controls, with more robust effects of MA withdrawal observed in MA high drinking than DBA/2J mice. When depression-like symptoms were examined after 1 or 2 weeks of forced abstinence in MA high drinking mice, depression-like symptoms dissipated, and subsequent MA intake was high. The MA high drinking genetic mouse model has strong face validity for human binge MA use and behavioral sequelae associated with abstinence.

Citing Articles

Neuropharmacological Evidence Implicating Drug-Induced Glutamate Receptor Dysfunction in Affective and Cognitive Sequelae of Subchronic Methamphetamine Self-Administration in Mice.

Denning C, Madory L, Herbert J, Cabrera R, Szumlinski K Int J Mol Sci. 2024; 25(3).

PMID: 38339206 PMC: 10856401. DOI: 10.3390/ijms25031928.

Withdrawal: A key consideration in evaluating whether highly processed foods are addictive.

Parnarouskis L, Leventhal A, Ferguson S, Gearhardt A Obes Rev. 2022; 23(11):e13507.

PMID: 36196649 PMC: 9786266. DOI: 10.1111/obr.13507.

Goofballing of Opioid and Methamphetamine: The Science Behind the Deadly Cocktail.

Hazani H, Naina Mohamed I, Muzaimi M, Mohamed W, Yahaya M, Teoh S Front Pharmacol. 2022; 13:859563.

PMID: 35462918 PMC: 9021401. DOI: 10.3389/fphar.2022.859563.

A Zebrafish Model of Neurotoxicity by Binge-Like Methamphetamine Exposure.

Bedrossiantz J, Bellot M, Dominguez-Garcia P, Faria M, Prats E, Gomez-Canela C Front Pharmacol. 2021; 12:770319.

PMID: 34880760 PMC: 8646101. DOI: 10.3389/fphar.2021.770319.

Optimizing outpatient treatment outcomes among methamphetamine-using gay and bisexual men through a computerized depression intervention.

Fletcher J, Reback C J Subst Abuse Treat. 2021; 136:108663.

PMID: 34801284 PMC: 8940664. DOI: 10.1016/j.jsat.2021.108663.

References

Jang C, Whitfield T, Schulteis G, Koob G, Wee S . A dysphoric-like state during early withdrawal from extended access to methamphetamine self-administration in rats. Psychopharmacology (Berl). 2012; 225(3):753-63. PMC: 3547144. DOI: 10.1007/s00213-012-2864-0. View

Roberts D, Gabriele A, Zimmer B . Conflation of cocaine seeking and cocaine taking responses in IV self-administration experiments in rats: methodological and interpretational considerations. Neurosci Biobehav Rev. 2013; 37(9 Pt A):2026-36. PMC: 3838507. DOI: 10.1016/j.neubiorev.2013.04.017. View

Cryan J, Hoyer D, Markou A . Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry. 2003; 54(1):49-58. DOI: 10.1016/s0006-3223(02)01730-4. View

Szumlinski K, Lominac K, Campbell R, Cohen M, Fultz E, Brown C . Methamphetamine Addiction Vulnerability: The Glutamate, the Bad, and the Ugly. Biol Psychiatry. 2016; 81(11):959-970. PMC: 5391296. DOI: 10.1016/j.biopsych.2016.10.005. View

Neisewander J, Cheung T, Pentkowski N . Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development. Neuropharmacology. 2013; 76 Pt B:301-19. PMC: 4041184. DOI: 10.1016/j.neuropharm.2013.08.014. View

Rawson R, Huber A, Brethen P, Obert J, Gulati V, Shoptaw S . Status of methamphetamine users 2-5 years after outpatient treatment. J Addict Dis. 2002; 21(1):107-19. DOI: 10.1300/j069v21n01_09. View

Shabani S, McKinnon C, Reed C, Cunningham C, Phillips T . Sensitivity to rewarding or aversive effects of methamphetamine determines methamphetamine intake. Genes Brain Behav. 2011; 10(6):625-36. PMC: 3320762. DOI: 10.1111/j.1601-183X.2011.00700.x. View

Cryan J, Mombereau C, Vassout A . The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005; 29(4-5):571-625. DOI: 10.1016/j.neubiorev.2005.03.009. View

Cheng W, Garfein R, Semple S, Strathdee S, Zians J, Patterson T . Binge use and sex and drug use behaviors among HIV(-), heterosexual methamphetamine users in San Diego. Subst Use Misuse. 2009; 45(1-2):116-33. PMC: 2861916. DOI: 10.3109/10826080902869620. View

10.

Ripoll N, David D, Dailly E, Hascoet M, Bourin M . Antidepressant-like effects in various mice strains in the tail suspension test. Behav Brain Res. 2003; 143(2):193-200. DOI: 10.1016/s0166-4328(03)00034-2. View

11.

Jones H, Dean A, Price K, London E . Increased self-reported impulsivity in methamphetamine users maintaining drug abstinence. Am J Drug Alcohol Abuse. 2016; 42(5):500-506. PMC: 5055455. DOI: 10.1080/00952990.2016.1192639. View

12.

de Wit H, Uhlenhuth E, Johanson C . Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend. 1986; 16(4):341-60. DOI: 10.1016/0376-8716(86)90068-2. View

13.

Newton T, Kalechstein A, Duran S, Vansluis N, Ling W . Methamphetamine abstinence syndrome: preliminary findings. Am J Addict. 2004; 13(3):248-55. DOI: 10.1080/10550490490459915. View

14.

Cho A, Melega W, Kuczenski R, Segal D . Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse. 2001; 39(2):161-6. DOI: 10.1002/1098-2396(200102)39:2<161::AID-SYN7>3.0.CO;2-E. View

15.

Cruickshank C, Dyer K . A review of the clinical pharmacology of methamphetamine. Addiction. 2009; 104(7):1085-99. DOI: 10.1111/j.1360-0443.2009.02564.x. View

16.

Reed C, Baba H, Zhu Z, Erk J, Mootz J, Varra N . A Spontaneous Mutation in Impacts Methamphetamine-Related Traits Exclusively in DBA/2 Mice from a Single Vendor. Front Pharmacol. 2018; 8():993. PMC: 5786530. DOI: 10.3389/fphar.2017.00993. View

17.

Rawson R . Current research on the epidemiology, medical and psychiatric effects, and treatment of methamphetamine use. J Food Drug Anal. 2014; 21(4):S77-S81. PMC: 4158843. DOI: 10.1016/j.jfda.2013.09.039. View

18.

Phillips T, Kamens H, Wheeler J . Behavioral genetic contributions to the study of addiction-related amphetamine effects. Neurosci Biobehav Rev. 2008; 32(4):707-59. PMC: 2360482. DOI: 10.1016/j.neubiorev.2007.10.008. View

19.

Mancino M, Gentry B, Feldman Z, Mendelson J, Oliveto A . Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study. Am J Drug Alcohol Abuse. 2011; 37(2):131-6. PMC: 3063384. DOI: 10.3109/00952990.2010.543998. View

20.

Phillips T, Mootz J, Reed C . Identification of Treatment Targets in a Genetic Mouse Model of Voluntary Methamphetamine Drinking. Int Rev Neurobiol. 2016; 126():39-85. DOI: 10.1016/bs.irn.2016.02.001. View